4月27日，据CDE官网消息，士泽生物医药（上海）有限公司、士泽生物医药（苏州）有限公司联合申请药品“XS228细胞注射液”，获得临床试验默示许可，受理号CXSL2500121。
公示信息显示，药品“XS228细胞注射液”适应症：肌萎缩侧索硬化症（ALS）。
士泽生物医药（上海）有限公司，成立于2021年，位于上海市，是一家以从事专业技术服务业为主的企业。企业注册资本12000万人民币，实缴资本8500万人民币。
通过天眼查大数据分析，士泽生物医药（上海）有限公司参与招投标项目4次，专利信息3条，此外企业还拥有行政许可13个。
主要股东信息显示，士泽生物医药（上海）有限公司由士泽生物医药（苏州）有限公司持股100%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.